Axio BioPharma is an early-stage AI-powered biologics CDMO based in Madison, Wisconsin, specializing in high-throughput recombinant protein and monoclonal antibody manufacturing. Currently operating at non-GMP research grade, the company provides standardized small-volume screening and optimization services with rapid 3-5 week delivery, and partners with larger CDMOs for GMP production at scale. Axio is building an AI foundation for cross-site learning, faster tech-transfer, and predictive process control. Named an ICP Round 1 awardee through Forward BIOLABS, the company was founded in 2024 and is focused on accelerating early-stage biologics development through data-rich lab services.
AI-driven biomanufacturing, high-throughput antibody production, recombinant protein manufacturing, bioinformatics, data-driven process optimization
1 site worldwide
No certifications on file yet.
No reviews available yet.
No documents available.